Sera Prognostics Added to Russell 2000 and 3000 Indexes Following Conclusion of 2024 Indexes Annual Reconstitution July 1, 2024-Sera Prognostics
Sera Prognostics Announces Primary Endpoint Criteria Met in Pivotal Prime Study Interim Look – Enrollment to Stop Due to Success December 6, 2023-Sera Prognostics
Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO May 15, 2023-Sera Prognostics
Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL February 15, 2023-Sera Prognostics
Sera Prognostics Announces Publication of Data Predicting Clinical Utility and Cost Effectiveness of the PRETRM® Test-and-Treat Strategy Across Diverse Populations November 15, 2022-Sera Prognostics
Banner Health, Sera Prognosics Team Up to Provide PreTRM® Test to Cover Pregnant Members September 22, 2022-Sera Prognostics
Sera Prognostics Presents Data Demonstrating the Health & Economic Benefit of PRETRM® Testing at Ispor Annual Meeting May 20, 2022-Sera Prognostics
Sera Prognostics and Newborn Foundation Partner to Reduce Risks Associated with Preterm Birth and Improve Health Equity Through the “Every Mother, Every Baby” Project May 5, 2022-Sera Prognostics
